Experimental Oncology and Biobanking Unit, Heredo-Familiar Cancer Clinic, IRCCS - Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Molecular Diagnostics and Pharmacogenetics Unit, IRCCS - Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Fam Cancer. 2023 Jan;22(1):43-48. doi: 10.1007/s10689-022-00307-y. Epub 2022 Jul 22.
During Covid-19 pandemic most hospitals have restricted in-person delivery of non-essential healthcare services, including genetic testing delivery, to slow the spread of the virus. Our Onco-Genetic Service also faced this challenging period and had to re-organize its clinical practice with the use of tele-health. Aim of the present paper is to understand whether and how Covid-19-related changes in medical practice influenced patients' satisfaction about the health service provided. 125 BRCA1/2 non carriers (109/125, 87.2% female and 16/125, 12.8% male) in Istituto Tumori "Giovanni Paolo II" of Bari were enrolled. All participants were asked to choose whether they prefer in-person or remote post-test counselling session. Basing on patients' choice, two groups of subjects were composed. One week after the post-test counselling session, participants were phone called and asked to complete: a socio-demographic form, a brief structured interview about their Covid-19 related worries and their satisfaction with the health service provided, Hospital Anxiety and Depression Scale and Fear of Covid-19 scale. Qualitative information about patients' choice were also collected. No significant difference about patients' satisfaction with the health service provided emerged between groups. Patients who preferred remote post-test counselling had higher anxiety, worries and fear-of Covid-19 than the others. All remote-counselling subjects preferred tele-genetics because of Covid-19 security, would choose it again and would recommend it to others. Cancer tele-genetics offers good guarantees of comfort and efficacy, but patients' choices are related to personal and psychological variables. The use of tele-genetics has to be a patient's choice.
在 COVID-19 大流行期间，大多数医院都限制了非必要的医疗保健服务（包括基因检测服务）的亲自交付，以减缓病毒的传播。我们的肿瘤遗传服务也面临着这一具有挑战性的时期，不得不使用远程医疗重新组织其临床实践。本文的目的是了解 COVID-19 相关的医疗实践变化是否以及如何影响患者对所提供医疗服务的满意度。我们招募了巴里 Istituto Tumori“Giovanni Paolo II”的 125 名 BRCA1/2 非携带者（109/125，87.2%为女性，16/125，12.8%为男性）。所有参与者都被要求选择他们是更喜欢亲自参加还是远程参加检测后咨询会议。根据患者的选择，将两组受试者组成。在检测后咨询会议一周后，通过电话联系参与者，并要求他们完成：一份社会人口统计学表格、一份关于他们与 COVID-19 相关的担忧以及对所提供医疗服务的满意度的简短结构化访谈、医院焦虑和抑郁量表以及对 COVID-19 的恐惧量表。还收集了有关患者选择的定性信息。两组之间在对所提供医疗服务的满意度方面没有显著差异。更喜欢远程检测后咨询的患者比其他人有更高的焦虑、担忧和对 COVID-19 的恐惧。所有远程咨询的受试者都因为 COVID-19 的安全性而更喜欢远程遗传咨询，会再次选择它，并会向他人推荐。癌症远程遗传咨询提供了良好的舒适感和疗效保证，但患者的选择与个人和心理变量有关。远程遗传咨询的使用必须是患者的选择。
